Liver Cirrhosis, Biliary Clinical Trial
— CBP-HOPEOfficial title:
Randomized Controlled Trial of Psychoeducational and Hypnosis Interventions on the Fatigue Associated With Primary Biliary Cholangitis in Women (CBP-HOPE)
NCT number | NCT03630718 |
Other study ID # | K180401J |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | May 27, 2019 |
Est. completion date | May 22, 2023 |
Verified date | February 2024 |
Source | Assistance Publique - Hôpitaux de Paris |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Fatigue is a clinical symptom that has been described as the most disturbing by around 50% of patients with PBC. It has an important impact on patients' quality of life and is associated with an increased mortality risk. To treat fatigue in PBC, only medical treatments have been tested with limited efficacy or serious sides' effects. In other diseases, mostly cancer, psychological interventions showed efficacy on fatigue decrease. Most interventions consist in psychoeducation with: education about fatigue, development of self-care or coping techniques, activity management and learning to balance between activities and rest. Hypnosis, which consists in a body work for psycho-therapeutic use (e.g., through imagination), has also shown promising results. Moreover, psychological intervention efficacy seems to be influenced by patients' characteristics, such as personality. Therefore, the first aim of the present single-center randomized controlled phase 2 trial is to assess the efficacy of a psycho educational intervention and a hypnosis intervention on PBC patients' fatigue to demonstrate that both psychoeducational and hypnosis interventions decrease patient fatigue.
Status | Completed |
Enrollment | 55 |
Est. completion date | May 22, 2023 |
Est. primary completion date | May 17, 2023 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Women from 18 to 75 years old, - Diagnosis of primary biliary cholangitis (PBC) according to recognized criteria (EASL 2017), - Medically stable under treatment with UDCA initiated for at least 6 months, ie medically stable on the basis of liver biological parameters (no increase of more than 20% in bilirubin, ALP and transaminases) and absence of disabling pruritus (permanent and EVA> 6/10 or scratching lesions), - Presenting a significant level of fatigue (fatigue score on PBC-40>= 33), - Understanding the French language, - Availability and ability of the patient to access an internet network terminal to answer the online questionnaires of the study, - Signed consent form. Exclusion Criteria: - Presence of cirrhosis with a Child-Pugh B or C, - Presence of disabling pruritus (permanent, or EVA>= 7/10 in the last 3 weeks, or objectivable scratching skin lesions), - Patient on liver transplantation waiting list or total bilirubin> 50 µmol / L (3 mg / dL), or recent complication (<6 months) of cirrhosis (ascites, hepatic encephalopathy, rupture bleeding) of esophageal varices), - Untreated depressive disorder, - Any comorbidity not medically controlled (i.e. all dosage changes <3 months due to a control of the associated pathology deemed insufficient by the referring physician) or life-threatening in the medium term (within 2 years). - Psychiatric disorder modifying the relationship to the reality |
Country | Name | City | State |
---|---|---|---|
France | Service hépatologie Hôpital Saint-Antoine | Paris |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris | University of Paris 5 - Rene Descartes |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Multidimensional fatigue inventory (MFI) (1) | At Day 0 | ||
Primary | Multidimensional fatigue inventory (MFI) (2) | At week 5 | ||
Primary | Multidimensional fatigue inventory (MFI) (3) | At month 3 | ||
Primary | Multidimensional fatigue inventory (MFI) (4) | At month 6 | ||
Secondary | Short Form Health Survey (SF36) (1) | At Day 0 | ||
Secondary | Short Form Health Survey (SF36) (2) | At week 5 | ||
Secondary | Short Form Health Survey (SF36) (3) | At month 3 | ||
Secondary | Short Form Health Survey (SF36) (4) | At month 6 | ||
Secondary | PBC-40 questionaire (1) | At Day 0 | ||
Secondary | PBC-40 questionaire (2) | At week 5 | ||
Secondary | PBC-40 questionaire (3) | At month 3 | ||
Secondary | PBC-40 questionaire (4) | At month 6 | ||
Secondary | Pittsburg Sleep Quality Inventory (PSQI) (1) | At Day 0 | ||
Secondary | Pittsburg Sleep Quality Inventory (PSQI) (2) | At week 5 | ||
Secondary | Pittsburg Sleep Quality Inventory (PSQI) (3) | At month 3 | ||
Secondary | Pittsburg Sleep Quality Inventory (PSQI) (4) | At month 6 | ||
Secondary | Epworth Sleeping Scale (ESS) (1) | At Day 0 | ||
Secondary | Epworth Sleeping Scale (ESS) (2) | At week 5 | ||
Secondary | Epworth Sleeping Scale (ESS) (3) | At month 3 | ||
Secondary | Epworth Sleeping Scale (ESS) (4) | At month 6 | ||
Secondary | Hospital Anxiety and Depression Scale (HADS) (1) | At Day 0 | ||
Secondary | Hospital Anxiety and Depression Scale (HADS) (2) | At week 5 | ||
Secondary | Hospital Anxiety and Depression Scale (HADS) (3) | At month 3 | ||
Secondary | Hospital Anxiety and Depression Scale (HADS) (4) | At month 6 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02917408 -
Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital
|
||
Terminated |
NCT00550862 -
Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)
|
Phase 2 | |
Completed |
NCT00004748 -
Low-Dose Oral Methotrexate Versus Colchicine for Primary Biliary Cirrhosis
|
Phase 3 | |
Completed |
NCT00004842 -
Pilot Study of Budesonide for Patients With Primary Sclerosing Cholangitis
|
Phase 1 | |
Terminated |
NCT03633227 -
Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment
|
Phase 4 | |
Terminated |
NCT00125281 -
SAMe to Treat Biliary Cirrhosis Symptoms
|
Phase 2 | |
Completed |
NCT04629456 -
Physical Therapy for Liver Cirrhosis
|
N/A | |
Completed |
NCT03468699 -
Autologous Bone Marrow Mononuclear Stem Cell for Children Suffering From Liver Cirrhosis Due to Biliary Atresia
|
Phase 2 | |
Completed |
NCT00004784 -
Phase III Randomized Study of Ursodiol With Vs Without Methotrexate for Primary Biliary Cirrhosis
|
Phase 3 | |
Completed |
NCT00006168 -
Ursodiol-Methotrexate for Primary Biliary Cirrhosis
|
Phase 3 | |
Completed |
NCT00570765 -
Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC)
|
Phase 2 | |
Recruiting |
NCT00160940 -
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis
|
N/A | |
Recruiting |
NCT03146910 -
Swiss Primary Biliary Cholangitis Cohort Study
|
||
Terminated |
NCT03265249 -
BRIDGE Device for Post-operative Pain Control
|
N/A | |
Terminated |
NCT02308111 -
Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis
|
Phase 4 | |
Recruiting |
NCT02936596 -
Remission Induction of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome
|
N/A | |
Completed |
NCT00406237 -
Pharmacokinetic Study Of Tigecycline In Adult Subjects With Primary Biliary Cirrhosis
|
Phase 1 | |
Completed |
NCT04047160 -
Safety, Tolerability of OP-724 in Patients With Primary Biliary Cholangitis (Phase I)
|
Phase 1 | |
Recruiting |
NCT00145964 -
Identification of the Genetic Variants Responsible for Primary Biliary Cirrhosis (PBC)
|
N/A | |
Terminated |
NCT03476993 -
Non-comparative Study of BCD-085 in Combination With UDCA in Patients With Primary Biliary Cholangitis
|
Phase 2 |